美国生物制药公司Madrigal Pharmaceuticals Inc.(MDGL)今日盘中大涨18.28%,股价一度触及253.55美元。引发这一疯涨的主要原因是该公司旗舰药品Rezdiffra在上一季度的出色表现。
数据显示,Rezdiffra在2024年第三季度实现销售额6220万美元,远超市场预期的3420万美元。作为全球首款获FDA批准的NASH(非酒精性脂肪性肝炎)治疗药物,这已是Rezdiffra连续第二个季度取得强劲上市表现,进一步增强了投资者对该药物潜在用药人群需求的信心。
分析人士认为,Madrigal公司在NASH疾病领域的先行者优势,加之其丰富的商业经验,将使该公司能够充分抓住NASH这一新兴市场的机遇。NASH疾病约影响着美国5%的人口,潜在患者基数庞大,市场前景广阔。Rezdiffra出色的销售业绩持续提振着投资者的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.